Clusters of severe vision loss due to endophthalmitis following bevacizumab injection related to a few instances of substandard and erroneous compounding practices have raised concerns about the off-label use of this drug in the United States. In response, legislative changes have led to improved regulation and increased monitoring of compounding pharmacies.